111 results on '"Verbaan H"'
Search Results
2. Ribavirin dosage in patients with HCV genotypes 2 and 3 who completed short therapy with peg-interferon α-2b and ribavirin
3. INCREASED POLYMERISATION OF PLASMA ALPHA-1-ANTI-CHYMOTRYPSIN IN HEPATITIS C INFECTED PATIENTS
4. Extrahepatic manifestations of chronic hepatitis C infection and the interrelationship between primary Sjögren's syndrome and hepatitis C in Swedish patients
5. HEPATITIS G VIRUS INFECTION IN PATIENTS WITH CHRONIC LIVER DISEASE AND IN THE GENERAL POPULATION IN SOUTHERN SWEDEN
6. POLYMERIZATION OF PLASMA ALPHA-1-ANTICHYMOTRYPSIN IN HEPATITIS C INFECTED PATIENTS
7. Factors associated with cirrhosis development in chronic hepatitis C patients from an area of low prevalence
8. C05/02 ANCA IN PATIENTS WITH CHRONIC LIVER DISEASE; PREVALENCE, ANTIGEN SPECIFICITY AND PREDICTIVE VALUE FOR AUTOIMMUNE LIVER DISEASE
9. C03/08 The prevalence of gallstone disease (GD) in patients with chronic liver diseases (CLD) is related to severity and etiology
10. C01/95 THE PREVALENCE OF CHRONIC VIRAL HEPATITIS IN A SWEDISH LOW RISK URBAN POPULATION
11. The clinical importance in differentiating portal from mesenteric venous thrombosis
12. Clinical trial : colectomy after resue therapy in ulcerative colitis-3-year follow-up of the Swedish-Danish controlled infliximab study
13. Cyclosporin eller infliximab som rescue terapi vid steroidfraktär ulcerös kolit : en retrospective observationsstudie
14. In patients with HCV genotype 2 or 3 infection and RVR 14 weeks treatment is noninferior to 24 weeks:pooled analysis of two Scandinavian trials
15. Ribavirin dosage in patients with HCV genotypes 2 and 3 who completed short therapy with peg-interferon alpha-2b and ribavirin
16. Outcome of rescue therapy in steroid-resistant ulcerative colitis : a retrospective study comparing cyclosporine and infliximab
17. Colectomy after rescue therapy for intravenous-steroid resistant acute ulcerative colitis : a 3-year follow-up study of the Swedish-Danish infliximab/placebo trial
18. PIN37 The Cost of Managing Chronic Hepatitis C in Sweden - Medical Resource Utilisation in Different Stages of the Disease
19. 412 THE USEFULNESS OF DEFINING RVR BY A VERY SENSITIVE ASSAY DURING THE TREATMENT OF HCV GENOTYPE 3 INFECTION; A COMPARISON OF TMA AND AMPLICOR
20. 1151 GENETIC VARIANTS AT ITPA THE LOCUS PROTECTS AGAINST RIBAVIRIN-INDUCED HEMOLYTIC ANEMIA – A REPLICATION STUDY IN A SCANDINAVIAN HCV G2/G3 COHORT
21. 630 RIBAVIRIN (RBV) DOSAGE AS INDEPENDENT PREDICTOR OF RVR IN HCV GENOTYPE 2 (HCV-2) AND 3 (HCV-3) PATIENTS UNDERGOING COMBINED TREATMENT WITH PEG INTERFERON (PEG-IFN) ALPHA-2B
22. 728 IS SUSTAINED VIROLOGICAL RESPONSE TO HCV TREATMENT ASSOCIATED WITH A CLINICAL IMPORTANT IMPROVEMENT IN VITALITY?
23. [128] PEGINTERFERON o-2b AND RIBAVIRIN FOR 14 OR 24 WEEKS IN PATIENTS WITH HCV GENOTYPE 2 OR 3 AND RAPID VIROLOGICAL RESPONSE. THE NORTH-C TRIAL
24. A randomised, double blind, placebo controlled trial of interferon alpha2b with and without ribavirin in mild chronic hepatitis C infection
25. Non-Invasive Assessment of Inflammatory Activity and Fibrosis (Grade and Stage) in Chronic Hepatitis C Infection
26. Alcohol Abuse Exaggerates Autonomic Dysfunction in Chronic Liver Disease
27. Intravenous Drug Abuse–the Major Route of Hepatitis C Virus Transmission among Alcohol-Dependent Individuals?
28. Hepatitis C in chronic liver disease: an epidemiological study based on 566 consecutive patients undergoing liver biopsy during a 10‐year period
29. In patients with HCV genotype 2 or 3 infection and RVR 14 weeks treatment is noninferior to 24 weeks. Pooled analysis of two Scandinavian trials.
30. Prevalence of hepatitis C in Swedish diabetics is low and comparable to that in health care workers.
31. Prevalence and Clinical Spectrum of Chronic Viral Hepatitis in a Middle-aged Swedish General Urban Population.
32. Long-Term Outcome of Chronic Hepatitis C Infection in a Low-Prevalence Area.
33. Partial splenic embolization as pretreatment for antiviral therapy in hepatitis C virus infection.
34. Serine protease inhibitors in patients with chronic viral hepatitis
35. The clinical importance in differentiating portal from mesenteric venous thrombosis
36. Wireless Capsule Enteroscopy: A Comparison with Enterography, Push Enteroscopy and Ileo-colonoscopy in the Diagnosis of Small Bowel Crohn's Disease
37. Mycophenolate mofetil treatment in patients with autoimmune hepatitis failing standard therapy with prednisolone and azathioprine.
38. Increased hope following successful treatment for hepatitis C infection.
39. Epidemiology and causes of death in a Swedish cohort of patients with autoimmune hepatitis.
40. Histological improvement of liver fibrosis in well-treated patients with autoimmune hepatitis: A cohort study.
41. [Acute renal failure is a common complication in liver cirrhosis].
42. The Usefulness of Defining Rapid Virological Response by a Very Sensitive Assay (TMA) during Treatment of HCV Genotype 2/3 Infection.
43. Peg-IFN and ribavirin treatment for recurrence of genotype 2 and 3 hepatitis C after liver transplantation.
44. Hepatocellular and extrahepatic cancer in patients with autoimmune hepatitis--a long-term follow-up study in 634 Swedish patients.
45. A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis.
46. Genetic variants at the ITPA locus protect against ribavirin-induced hemolytic anemia and dose reduction in an HCV G2/G3 cohort.
47. Infliximab or cyclosporine as rescue therapy in hospitalized patients with steroid-refractory ulcerative colitis: a retrospective observational study.
48. IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection.
49. The clinical importance in differentiating portal from mesenteric venous thrombosis.
50. Ribavirin dosage in patients with HCV genotypes 2 and 3 who completed short therapy with peg-interferon alpha-2b and ribavirin.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.